These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17848182)

  • 1. Individualized population pharmacokinetic model with limited sampling for cyclosporine monitoring after liver transplantation in clinical practice.
    Langers P; Cremers SC; den Hartigh J; Rijnbeek EM; Ringers J; Lamers CB; Hommes DW; van Hoek B
    Aliment Pharmacol Ther; 2007 Nov; 26(10):1447-54. PubMed ID: 17848182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Easy-to-use, accurate and flexible individualized Bayesian limited sampling method without fixed time points for ciclosporin monitoring after liver transplantation.
    Langers P; Cremers SC; den Hartigh J; Rijnbeek EM; Ringers J; Lamers CB; van Hoek B
    Aliment Pharmacol Ther; 2005 Mar; 21(5):549-57. PubMed ID: 15740538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flexible limited sampling model for monitoring tacrolimus in stable patients having undergone liver transplantation with samples 4 to 6 hours after dosing is superior to trough concentration.
    Langers P; Press RR; den Hartigh J; Cremers SC; Baranski AG; Lamers CB; Hommes DW; van Hoek B
    Ther Drug Monit; 2008 Aug; 30(4):456-61. PubMed ID: 18641539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decision support tool to individualize cyclosporine dose in stable, long-term heart transplant recipients receiving metabolic inhibitors: overcoming limitations of cyclosporine C2 monitoring.
    Ray JE; Keogh AM; McLachlan AJ
    J Heart Lung Transplant; 2006 Oct; 25(10):1223-9. PubMed ID: 17045935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, controlled trial of C0- Vs C2-guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients.
    Mathias HC; Ozalp F; Will MB; Borland W; Payne C; Kerr M; Lockhart J; Murday AJ
    J Heart Lung Transplant; 2005 Dec; 24(12):2137-43. PubMed ID: 16364862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited sampling strategy for cyclosporine (Neoral) area under the curve monitoring in pediatric kidney transplant recipients.
    Strong DK; Lai A; Primmett D; White CT; Lirenman DS; Carter JE; Hurley RM; Virji M; Ensom MH
    Pediatr Transplant; 2005 Oct; 9(5):566-73. PubMed ID: 16176411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching monitoring of emulsified cyclosporine from trough level to 2-hour level in stable liver transplant patients.
    Langers P; Cremers SC; den Hartigh J; Veenendaal RA; ten Hove WR; Ringers J; Lamers CB; van Hoek B
    Liver Transpl; 2004 Feb; 10(2):183-9. PubMed ID: 14762854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose.
    Sukhavasharin N; Praditpornsilpa K; Avihingsanon Y; Kuoatawintu P; O-Charoen R; Kansanabuch T; Tungsanga K; Eiam-Ong S
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S15-20. PubMed ID: 17044449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation.
    Hangler HB; Ruttmann E; Geltner C; Bucher B; Nagiller J; Laufer G; Mueller LC
    Clin Transplant; 2008; 22(1):35-40. PubMed ID: 18217903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral).
    Jaksch P; Kocher A; Neuhauser P; Sarahrudi K; Seweryn J; Wisser W; Klepetko W
    J Heart Lung Transplant; 2005 Aug; 24(8):1076-80. PubMed ID: 16102443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of area under the whole blood concentration versus time curve after first intravenous cyclosporine dose in children undergoing hematopoietic stem cell transplant: limited sampling strategies.
    Sibbald C; Seto W; Taylor T; Saunders EF; Doyle J; Dupuis LL
    Ther Drug Monit; 2008 Aug; 30(4):434-8. PubMed ID: 18641547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine.
    Figurski MJ; Nawrocki A; Pescovitz MD; Bouw R; Shaw LM
    Ther Drug Monit; 2008 Aug; 30(4):445-55. PubMed ID: 18641543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achieving adequate cyclosporine exposure in liver transplant recipients: a novel strategy for monitoring and dosing using intravenous therapy.
    Lück R; Böger J; Kuse E; Klempnauer J; Nashan B
    Liver Transpl; 2004 May; 10(5):686-91. PubMed ID: 15108262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes.
    Delgado DH; Rao V; Hamel J; Miriuka S; Cusimano RJ; Ross HJ
    J Heart Lung Transplant; 2005 Sep; 24(9):1343-6. PubMed ID: 16143255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
    Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Hübler M; Abd El Rahman MY; Miera O; Ewert P; Weng Y; Wei H; Krüdewagen B; Hetzer R; Berger F
    J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
    Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
    Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values.
    Troncoso P; Ortiz AM; Jara A; Vilches S
    Transplant Proc; 2009; 41(1):127-30. PubMed ID: 19249495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
    Irtan S; Saint-Marcoux F; Rousseau A; Zhang D; Leroy V; Marquet P; Jacqz-Aigrain E
    Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-dependent changes in cyclosporine exposure: implications for achieving target concentrations.
    Felipe CR; Silva HT; Machado PG; Garcia R; Moreira SR; Pestana JO
    Transpl Int; 2003 Jul; 16(7):494-503. PubMed ID: 12677364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2).
    Brunet M; Campistol JM; Millán O; Vidal E; Esforzado N; Rojo I; Jiménez O; Oppenheimer F; Corbella J; Martorell J
    Int Immunopharmacol; 2003 Jul; 3(7):987-99. PubMed ID: 12810356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.